Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
about
Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancerP53 expression is significantly correlated with high risk of malignancy and epithelioid differentiation in GISTs. An immunohistochemical study of 104 cases.Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis.Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal typeImmune cells in primary and metastatic gastrointestinal stromal tumors (GIST).Loss of chromosome 9p21 and decreased p16 expression correlate with malignant gastrointestinal stromal tumor.Genetic aberrations of gastrointestinal stromal tumors.Emerging roles of E2Fs in cancer: an exit from cell cycle controlPrognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysisExpression of DOG1, PDGFRA, and p16 in Gastrointestinal Stromal TumorsAn update on molecular genetics of gastrointestinal stromal tumours.Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.Genomic Grade Index predicts postoperative clinical outcome of GIST.Duodenal GIST: a single center experiencep16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome.Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor.Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.A meta-analysis of prognostic value of KIT mutation status in gastrointestinal stromal tumorsMolecular and functional characterization of a new 3' end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant ImatinibCyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors.Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.Heterozygosity loss at 22q and lack of INI1 gene mutation in gastrointestinal stromal tumor.Epithelioid/mixed phenotype in gastrointestinal stromal tumors with KIT mutation from the stomach is associated with accelerated passage of late phases of the cell cycle and shorter disease-free survival.Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation ofSPP1as an independent prognostic factor
P2860
Q28741689-9D53FC68-4D1F-48CA-A3D7-DB1271168E4EQ33354638-8ECB4DFF-6F65-45B6-9884-5DF0D2DAD8C8Q33712862-9D0F175C-26FE-47DA-A8DB-B4A982A472C8Q33995919-05D7B7D7-C377-4A0E-B349-BAE72EFF05EAQ34028872-0E5452BF-9DDA-4EFC-9BFF-DF4D1BD26F45Q34183218-B0ABA773-07DA-4C0F-A33A-F182329A717EQ34594996-45CF783C-E116-42FC-9661-E42DC363D21DQ35009182-3C082E22-2EB6-40D7-B145-B48F460A0EE2Q35051310-6B98EB7F-5D29-4E09-B593-11AE2B329979Q35119141-DFB9D447-C3E2-4440-9ED5-17A82AAB6CCCQ35770066-892B156C-980B-4679-B198-2D13FDC9D249Q35789573-CEEF6439-53CB-422A-8811-994687A3005EQ36387916-6219D0FA-EE05-4604-9E65-909B2D690336Q36803986-DE7F5C3D-DCE4-4BFC-985D-6DC62FC9E554Q36897784-75942721-9B14-4316-817E-2881C1CA426DQ38071053-E1CF6B16-2226-49E9-A31C-095037351C8EQ38237693-1BE6C83E-C991-46F6-8822-382C7C5B5B2AQ38925022-483E0366-D628-48CB-8DFB-164938D83D93Q39650027-3101E320-9C40-4689-9559-5F3F8EBECC57Q41347601-F6C8B06B-29AD-497D-94B0-EA14571BBEDEQ41365125-3CA37E17-968D-4E81-B838-3A2D3DBEFCA4Q49924821-7A6268C6-39C6-4F9C-B154-19236A122EEEQ50435067-88E9737A-F8D0-4C70-A207-5BCB87426377Q51232554-9C109E86-A497-4EC6-ABC6-589E5B440B78Q54587404-CA5344ED-6E9B-4B53-BC9F-6A77117C08CFQ54650490-34169136-C85E-4631-A468-4C1546971CC3Q57325993-82E3D8B5-3495-4EA1-A0B7-E38C8ED4FA18
P2860
Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Prognostic role of E2F1 and me ...... strointestinal stromal tumors.
@en
Prognostic role of E2F1 and me ...... strointestinal stromal tumors.
@nl
type
label
Prognostic role of E2F1 and me ...... strointestinal stromal tumors.
@en
Prognostic role of E2F1 and me ...... strointestinal stromal tumors.
@nl
prefLabel
Prognostic role of E2F1 and me ...... strointestinal stromal tumors.
@en
Prognostic role of E2F1 and me ...... strointestinal stromal tumors.
@nl
P2093
P1476
Prognostic role of E2F1 and me ...... astrointestinal stromal tumors
@en
P2093
Anja von Heydebreck
Bastian Gunawan
Claus Langer
Florian Haller
Giuliano Ramadori
Judith Wolf-Salgó
László Füzesi
Stefanie Schwager
P304
P356
10.1158/1078-0432.CCR-05-0329
P407
P577
2005-09-01T00:00:00Z